Overview
- Mass General Brigham’s VIVID randomized trial enrolled 1,747 adults with recent COVID-19 and 277 household contacts across the United States and Mongolia.
- Participants began supplements about three days after a positive test and received vitamin D3 at 9,600 IU for two days then 3,200 IU daily for four weeks, or placebo.
- Primary analyses showed no reduction in acute symptom severity, healthcare visits, or deaths, and no decrease in household transmission with vitamin D.
- Among participants who adhered to the regimen, 21% on vitamin D reported lingering symptoms at eight weeks versus 25% on placebo, a borderline difference.
- The results, published in The Journal of Nutrition, note remote conduct and post-diagnosis timing as limitations and disclose donated capsules and a coauthor’s Capitainer AB link.